Go Pro
OTCMKTS:ARNI

Arno Therapeutics (ARNI) Stock Price, News & Analysis

Arno Therapeutics logo

About Arno Therapeutics Stock (OTCMKTS:ARNI)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
8,820 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Arno Therapeutics, Inc. (OTCMKTS:ARNI) is a development‐stage biopharmaceutical company focused on the research and development of targeted therapeutics for oncology indications and rare genetic disorders. The company’s mission is to apply innovative biologic and protein engineering platforms to create therapies that address significant unmet medical needs in cancer and inherited metabolic conditions.

Arno’s pipeline centers on antibody‐based drug conjugates and recombinant fusion proteins designed to selectively target tumor cells or restore deficient enzyme activity in rare diseases. Although its programs remain in preclinical and early development stages, the company has secured intellectual property rights and in‐licensed technologies to advance multiple candidates toward Investigational New Drug (IND) filings.

To bolster its research efforts, Arno Therapeutics has entered into collaboration and licensing agreements with academic institutions and specialized biotechnology firms. These partnerships grant access to novel targeting platforms, enhance preclinical data generation and support scale‐up activities in anticipation of future clinical trials. The company aims to leverage these relationships to accelerate development timelines and de‐risk its lead programs.

Headquartered in Delray Beach, Florida, Arno Therapeutics is led by a management team with experience in biopharmaceutical development, clinical operations and regulatory affairs. The company continues to build its organizational capabilities, with the goal of advancing its pipeline and establishing a presence in U.S. and select international markets upon achieving clinical milestones.

AI Generated. May Contain Errors.

Receive ARNI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARNI Stock News Headlines

The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
ARNI Arno Therapeutics, Inc. - Seeking Alpha
See More Headlines

ARNI Stock Analysis - Frequently Asked Questions

Shares of ARNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arno Therapeutics investors own include Ampliphi Biosciences (APHB), Armata Pharmaceuticals (ARMP), Aurora Cannabis (ACB), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS) and

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:ARNI
CIK
1195116
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (OTCMKTS:ARNI) was last updated on 8/21/2026 by MarketBeat.com Staff.
From Our Partners